ClearBridge Investments, an investment management firm, published its “All Cap Growth Strategy” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. On an absolute basis, the Strategy generated gains across seven of the eight sectors in which it was invested (out of 11 sectors total). The primary contributors to performance were the IT and health care sectors while the sole detractor was the communication services sector Spare some time to check the fund’s top 5 holdings to have a clue about their top bets for 2022.
ClearBridge All Cap Growth Strategy, in its Q4 2021 investor letter, mentioned Charles River Laboratories International, Inc. (NYSE:CRL) and discussed its stance on the firm. Founded in 1947, Charles River Laboratories International, Inc. (NYSE:CRL) is a Wilmington, Massachusetts-based pharmaceutical company with a $14.5 billion market capitalization, and is currently spearheaded by its CEO, James C. Foster. Charles River Laboratories International, Inc. (NYSE:CRL) delivered a -23.39% return since the beginning of the year, while its 12-month returns are down by -4.94%. The stock closed at $287.27 per share on April 04, 2022.
Here is what ClearBridge All Cap Growth Strategy has to say about Charles River Laboratories International, Inc. (NYSE:CRL) in its Q4 2021 investor letter:
“Health care also provides a good example of industry diversification as we look beyond our historical foundation in biotechnology and pharmaceutical companies to other promising areas like life sciences, tools and lab services. We recently added Charles River Laboratories, a leading drug discovery, non-clinical development and manufacturing organization which serves a large and growing market that is being driven by research & development/biologics manufacturing and increased outsourcing. The company is also well-positioned to benefit from rapid growth in cell and gene therapies on the heels of recent M&A activity. The business is a solid free cash flow generator and should continue to see further operating leverage on the back of topline growth.
Pressmaster/Shutterstock.com
Our calculations show that Charles River Laboratories International, Inc. (NYSE:CRL) failed to obtain a mark on our list of the 30 Most Popular Stocks Among Hedge Funds. Charles River Laboratories International, Inc. (NYSE:CRL) was in 49 hedge fund portfolios at the end of the fourth quarter of 2021, compared to 46 funds in the previous quarter. Charles River Laboratories International, Inc. (NYSE:CRL) delivered a -17.40% return in the past 3 months.
In December 2021, we also shared another hedge fund’s views on Charles River Laboratories International, Inc. (NYSE:CRL) in another article. You can find other letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q4 page.
Disclosure: None. This article is originally published at Insider Monkey.
